Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1967 Aug;104(2):565–569. doi: 10.1042/bj1040565

The fate of [14C]thalidomide in the pregnant rabbit

S Fabro 1, R L Smith 1, R T Williams 1
PMCID: PMC1270621  PMID: 6048798

Abstract

1. The fate of [14C]thalidomide orally administered to pregnant rabbits at the beginning of the sensitive phase of pregnancy has been studied. 2. After the oral administration of [14C]thalidomide on the 192nd hour of pregnancy about 68% of the radioactivity appears in the urine and 22% in the faeces. 3. The urinary 14C is made up as follows (% of dose): thalidomide (2); α-(o-carboxybenzamido)glutarimide (16); 2- and 4-phthalimidoglutaramic acids (11); 2-phthalimidoglutaric acid (0·2); 2- and 4-(o-carboxybenzamido)glutaramic acids and 2-(o-carboxybenzamido)-glutaric acid (29). 4. The plasma 14C concentration is maximal at 12hr. after dosing and the radioactivity persists for more than 58hr. At 4hr. the main compound in the plasma is thalidomide, but its concentration steadily declines while the concentration of its hydrolysis products increases. 5. At 12, 24 and 58hr. after dosing radioactivity is present in the embryo and the maternal tissues examined. The 14C concentration in the embryo is at nearly all times higher than that in the plasma, brain, skeletal muscle and fat but lower than that in the liver and kidney. 6. At 4hr. after dosing the mother on the tenth day of pregnancy the specific activities of the embryo and the yolk-sac fluid are similar. 7. Thalidomide is found in the embryo together with seven of its hydrolysis products for more than 24hr. after dosing. The accumulation of radioactivity in the embryo is due to retention of the polar hydrolysis products.

Full text

PDF
565

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BECKMANN R. [C-14])]. Arzneimittelforschung. 1963 Mar;13:185–191. [PubMed] [Google Scholar]
  2. BECKMANN R. [On the behavior of thalidomide in the organism. 1]. Arzneimittelforschung. 1962 Nov;12:1095–1098. [PubMed] [Google Scholar]
  3. FABRO S., SCHUMACHER H., SMITH R. L., WILLIAMS R. T. IDENTIFICATION OF THALIDOMIDE IN RABBIT BLASTOCYSTS. Nature. 1964 Mar 14;201:1125–1126. doi: 10.1038/2011125a0. [DOI] [PubMed] [Google Scholar]
  4. Fabro S., Schumacher H., Smith R. L., Stagg R. B., Williams R. T. The metabolism of thalidomide: some biological effects of thalidomide and its metabolites. Br J Pharmacol Chemother. 1965 Oct;25(2):352–362. doi: 10.1111/j.1476-5381.1965.tb02055.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fabro S., Smith R. L. The teratogenic activity of thalidomide in the rabbit. J Pathol Bacteriol. 1966 Apr;91(2):511–519. doi: 10.1002/path.1700910227. [DOI] [PubMed] [Google Scholar]
  6. Fabro S., Smith R. L., Williams R. T. The fate of the hydrolysis products of thalidomide in the pregnant rabbit. Biochem J. 1967 Aug;104(2):570–574. doi: 10.1042/bj1040570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. KEBERLE H., LOUSTALOT P., MALLER R. K., FAIGLE J. W., SCHMID K. BIOCHEMICAL EFFECTS OF DRUGS ON THE MAMMALIAN CONCEPTUS. Ann N Y Acad Sci. 1965 Mar 12;123:252–262. doi: 10.1111/j.1749-6632.1965.tb12264.x. [DOI] [PubMed] [Google Scholar]
  8. KELLY R. G., PEETS E. A., GORDON S., BUYSKE D. A. Determination of C-14 and H3 in biological samples by Schoeniger combustion and liquid scintillation techniques. Anal Biochem. 1961 Jun;2:267–273. doi: 10.1016/s0003-2697(61)80010-9. [DOI] [PubMed] [Google Scholar]
  9. Schumacher H., Smith R. L., Williams R. T. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol Chemother. 1965 Oct;25(2):324–337. doi: 10.1111/j.1476-5381.1965.tb02053.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES